Table A3.
Data inputs for one-way sensitivity and scenario analysis (children in age group 5–15 years) Part 3.
| Value | Source | Explanations | Calculations | |
|---|---|---|---|---|
| Amount of RIG required for children 5–15 years for local wound + systemic infilteration | ||||
| Base case | 4.33 mL | Calculations | Population Projections for India and States 2011–2036 and Khadilkar (2019) | Age and gender specific proportionate weights and maximum dose calculations using NFHS-4 data and age specific weights in both the genders from Khadilkar V (2019) |
| Lower limit | 2.165 mL | Calculations | (−50% of base case) | |
| Upper limit | 6.495 mL | Calculations | (+50% of base case) | |
| Amount of RIG required for children 5–15 years for local wound infilteration | ||||
| Scenario 1 | 2.64 mL | Calculations | Bharti (2016) | For 5–10 years, Avg quantity = 2 mL No. of patients = 40, Total eRIG consumed = 2 × 40 = 80 mL For 10–15 years, Avg quantity = 3.5 mL, No. of patients = 30, Total eRIG consumed = 3.5 × 30 = 105 mL Total eRIG consumed (5–15 years) = 80 + 105 = 185 mL Average eRIG consumed = 185/70 = 2.64 mL |
| RIG access | 13.60% | WHO APCRI Survey 2017 | Assumptions from local + systemic infilteration from community survey | |
| Cost per dose of vaccine (per dose) | ||||
| Base case (INR 2020) | INR 250 | Procurement cost | Rate Contract (2020), Madhya Pradesh Aushadhi | |
| Lower limit (INR 2017) | INR 128 | WHO APCRI Survey 2017 | Average cost of vaccine purchased in study states | |
| Upper limit (INR 2017) | INR 325 | WHO APCRI Survey 2017 | Market cost per vial: Indian Immunologicals Ltd. | |
| Cost per eRIG vial; 5 mL | ||||
| Base case (INR 2017) | INR 313 | WHO APCRI Survey 2017 | Average cost of ERIG purchased in study states | |
| Lower limit (INR 2020) | INR 210 | Rate Contract (2020), MP Aushadhi | Procurement cost in MP | |
| Upper limit (INR 2017) | INR 476 | WHO APCRI Survey 2017 | Market cost per vial: Bharat Serums & Vaccines Ltd. | |
| Cost per HRIG vial (2 mL, 300 IU) (INR 2017) | ||||
| Scenario 2 | INR 3700 | WHO APCRI Survey 2017 | Average cost of the procurement value | Brand 1 = 3749, Brand 2 = 3650; Average = 3699.5 ~ 3700 |
| RIG access | 4.50% | WHO APCRI Survey 2017 | HRIG Administration in community survey | |
| Cost per vial of monoclonal antibodies (2.5 mL) (INR 2017) | ||||
| Scenario 3 | INR 1970 | WHO APCRI Survey 2017 | Market price as R-Mab in market surveillance phase | |
| R-Mab Access | 1% | Assumptions | Market Surveillance Phase | |
| Hospital charges (INR 2017) | ||||
| Base case | INR 3 | Government Facility, WHO APCRI Survey 2017 (Median Cost) | ||
| Lower limit | INR 2 | Government Facility, WHO APCRI Survey 2017 (Q1 of IQR) | ||
| Upper limit | INR 10 | Government Facility, WHO APCRI Survey 2017 (Q3 of IQR) | ||
| Cost of syringe (per unit) (INR 2020) | ||||
| Base case | INR 2.5 | Procurement costs (2020) | ||
| Lower limit | INR 1.25 | Calculations | −50% of the base case value) | |
| Upper limit | INR 3.75 | Calculations | (+50% of the base case value) | |
| Cost of gloves (per pair) (INR 2020) | ||||
| Base case | INR 14 | Procurement costs (2020) | ||
| Lower limit | INR 7 | Calculations | (−50% of the base case value) | |
| Upper limit | INR 21 | Calculations | (+50% of the base case value) | |
| Other medicines and consumables for PEP (1st visit only) (INR 2020) | ||||
| Base case | INR 169.8 | Calculated from WHO APCRI Survey 2017 | Cost reported in survey (inclusive of syringe + gloves) = 186.27; 186.27 − (2.5 + 14) = 169.77 | |
| Lower limit | INR 84.9 | Calculations | (−50% of the base case value) | 169.77 × 0.5 = 84.885 |
| Upper limit | INR 254.7 | Calculations | (+50% of the base case value) | 169.77 × 1.5 = 254.655 |
| Costs associated with human resources per visit (INR 2018) | ||||
| Base case | INR 87.39 | Calculations | National Health System Cost Database of India | |
| Lower limit | INR 69.91 | Calculations | (−20% of the base case value) | |
| Upper limit | INR 104.87 | Calculations | (+20% of the base case value) | |
| Travel cost for the patient/client and one attendant (per visit) (INR 2017) | ||||
| Base case | INR 50 | WHO APCRI Survey 2017 | ||
| Lower limit | INR 25 | Calculations | (−50% of the base case value) | |
| Upper limit | INR 75 | Calculations | (+50% of the base case value) | |
| Meal cost for the patient/client and one attendant (per visit) (INR 2017) | ||||
| Base case | INR 40 | WHO APCRI Survey 2017 | ||
| Lower limit | INR 20 | Calculations | (−50% of the base case value) | |
| Upper limit | INR 60 | Calculations | (+50% of the base case value) | |
| Loss of wages for one attendant (per visit) (INR 2020) | ||||
| Base case | INR 232 | Average state-wise per day wage rate for unskilled manual workers under MGNREGA | ||
| Lower limit | INR 190 | Lower limit of range reported in state-wise wage rate for unskilled manual workers (per day) under MGNREGA | ||
| Upper limit | INR 309 | Upper limit of range reported in state-wise wage rate for unskilled manual workers (per day) under MGNREGA | ||
| Treatment cost of fatal symptomatic rabies (per day) | ||||
| Base case | INR 3600 | Cost for intensive care services without ventilator as per PMJAY health benefit package 2.0 | ||
| Lower limit | INR 1800 | Calculations | (−50% of the base case value) | |
| Upper limit | INR 5400 | Calculations | (+50% of the base case value) | |
| Program management cost (per capita) (INR 2014) | ||||
| Base case | INR 0.2 | Calculated from Abbas (2014) | Program management costs (TN) = 14,388,443.689; Total population = 72,138,958; Per capita = 14,388,443.689/72,138,958 = 0.2 |
|
| Lower limit | INR 0.1 | Calculations | (−50% of the base case value) | |
| Upper limit | INR 0.3 | Calculations | (+50% of the base case value) | |
| Wastage factor vaccine | ||||
| Base case | 30% | Abbas (2014) | ||
| Lower limit | 15% | Calculations | (−50% of the base case value) | |
| Upper limit | 45% | Calculations | (+50% of the base case value) | |
| Wastage factor RIG | ||||
| Base case | 15% | Abbas (2014) | ||
| Lower limit | 7.5% | Calculations | (−50% of the base case value) | |
| Upper limit | 22.5% | Calculations | (+50% of the base case value) | |
| Discount rates | ||||
| Cost | 3% | WHO (2008) | ||
| Utility | 3% | WHO (2008) | ||